A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation. METHODS: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Secondary efficacy end points were derived from daily diaries and validated questionnaires completed by patients. Adverse events, clinical laboratory values, and cardiovascular effects were monitored. RESULTS: Efficacy was analyzed in 620 patients. The proportion of patients with three or more spontaneous, complete bowel movements per week was 30.9% of those receiving 2 mg of prucalopride and 28.4% of those receiving 4 mg of prucalopride, as compared with 12.0% in the placebo group (P<0.001 for both comparisons). Over 12 weeks, 47.3% of patients receiving 2 mg of prucalopride and 46.6% of those receiving 4 mg of prucalopride had an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group (P<0.001 for both comparisons). All other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment. CONCLUSIONS: Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation. Larger and longer trials are required to further assess the risks and benefits of the use of prucalopride for chronic constipation. (ClinicalTrials.gov number, NCT00483886 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Five 12-week randomized double-blinded placebo-controlled trials evaluated the use of prucalopride (2 mg daily) for the management of CIC. 75-79”
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
(1994) · Medical Entomology and Zoology · Cited by 4,156
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P. D., & Johanson, J. F. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,080
Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults
Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., Deckers, J. W., Kingma, J. H., Sturkenboom, M. C. J. M., Stricker, B. H. C., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.067 · Cited by 833
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citationChronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 584
Stewart, W. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00701-7 · Cited by 492
Psychometric Validation of a Constipation Symptom Assessment Questionnaire
L. Frank, L. K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750025327 · Cited by 458
The Health-Related Quality of Life and Economic Burden of Constipation
Dennison, C., Prasad, M., Lloyd, A., Bhattacharyya, S. K., Dhawan, R., & Coyne, K. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523050-00006 · Cited by 396
Research works printed but not linked: 3
- 10.1111/j.1572-0241.1999.01642.x · doi:10.1111/j.1572-0241.1999.01642.x · Paper page
- 10.1111/j.1572-0241.2002.05843.x · doi:10.1111/j.1572-0241.2002.05843.x · Paper page
- Schiller LR, 2004, Rev Gastroenterol Disord, 4, S43
Cited by
Items 301–400 of 581
Zheng, Y., Jiang, X., Gao, Y., Yuan, L., Wang, X., Wu, S., Xia, Y., Yao, L., Yan, J., Liu, L., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.737713 · Cited by 13
Tack, J. F., Derakhchan, K., Gabriel, A., Spalding, W. M., Terreri, B., Youssef, A. F., Kreidieh, B., Kowey, P. R., & Boules, M. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002249 · Cited by 15
Bielefeldt, K., Levinthal, D. J., & Nusrat, S. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15171 · Cited by 14
Malagelada, C., Nieto, A., Mendez, S., Accarino, A. M., Santos, J., Malagelada, J., & Azpiroz, F. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13733 · Cited by 13
Chronic Refractory Constipation in Children: Think Beyond Stools
Hasosah, M. Y. (2021) · Global Pediatric Health · doi:10.1177/2333794x211048739 · Cited by 14
Quantifying rigidity of Parkinson's disease in relation to laxative treatment: a service evaluation
Augustin, A. D., Charlett, A., Weller, C., Dobbs, S. M., Taylor, D. M., Bjarnason, I., & Dobbs, R. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12967 · Cited by 13
Kwong, W. J., Hammond, G., Upmalis, D. H., Okamoto, A., Yang, M. S., & Kavanagh, S. (2013) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e318274b695 · Cited by 14
New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety
Camilleri, M. (2011) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2011/527583 · Cited by 12
Self-citationLong, D. D., Armstrong, S. R., Beattie, D. T., Choi, S. K., Fatheree, P. R., Gendron, R. A. L., Goldblum, A. A., Humphrey, P. P. A., Marquess, D. G., Shaw, J., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.034 · Cited by 12
Prucalopride: the evidence for its use in the treatment of chronic constipation
Coremans, G. (2008) · Core evidence · doi:10.2147/ce.s7441 · Cited by 16
Haq, I., & Kilaru, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-59948-7 · Cited by 12
Disorders of Gastrointestinal Motility
Camilleri, M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00138-x · Cited by 15
Self-citationNew pharmacological treatment options for irritable bowel syndrome with constipation
Nusrat, S., & Miner, P. B. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1105215 · Cited by 12
Patient considerations in the management of chronic constipation: focus on prucalopride
Shin, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s92550 · Cited by 14
Parker, C. H., Yuan, Y., & Liu, L. W. C. (2013) · Clinical Medicine Insights Gastroenterology · doi:10.4137/cgast.s10550 · Cited by 11
Comparison of acupuncture and other drugs for chronic constipation: A network meta-analysis
Zhu, L., Ma, Y., & Deng, X. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196128 · Cited by 11
RetractedHong, J. T. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s269330 · Cited by 12
“Excluding AEs reported on day 1, the difference between prucalopride and placebo recipients in the incidence of these AEs was weak.(19,57,58,60) Discontinuation rates due to AEs were reported in the placebo (1.”
BackgroundNorton, C. S., Emmanuel, A. V., Stevens, N. J., Scott, S. M., Grossi, U., Bannister, S., Eldridge, S. M., Mason, J. M., & Knowles, C. H. (2017) · Trials · doi:10.1186/s13063-017-1880-0 · Cited by 11
Kim, S. Y., Woo, H. S., Kim, K. O., Choi, S. H., Kwon, K. A., Chung, J., Kim, Y. J., Kim, J. H., Kim, S. J., & Park, D. K. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13807 · Cited by 11
Chen, Z., Tan, M., Shan, C., Yuan, X., Chen, L., Shi, J., Lan, Y., & Li, Y. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202212160 · Cited by 10
Vázquez‐Roque, M. I., & Bouras, E. P. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0012-9 · Cited by 10
Emerging treatments for chronic constipation
Gudsoorkar, V. S., & Quigley, E. M. M. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.831068 · Cited by 10
“Women with idiopathic constipation suffer more anxiety, depression, somatization, and sexual dysfunction, which further impacts on QoL [6].”
BackgroundInfluentialYang, T., Wang, K., Cao, Y., Wen, J., Wei, S., Li, H., Yang, X., & Xiao, T. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-039461 · Cited by 10
Zeng, Y., & Chen, F. (2021) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001645 · Cited by 14
Zheng, C. H., Huang, G., Xu, X., Wang, Y., Zhang, M., Wang, W., Jing, X., & Zhu, B. (2013) · Trials · doi:10.1186/1745-6215-14-344 · Cited by 10
“N Engl J Med, 2008, 358 (22): 2344–2354 [11].”
Prucalopride-associated acute tubular necrosis
Sivabalasundaram, V., Habal, F., & Cherney, D. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i8.380 · Cited by 10
Groupe de travail du pôle qualité des soins et de l’accompagnement, S. F. D. E. D. S. P. (2009) · Médecine Palliative · doi:10.1016/s1636-6522(09)70064-9 · Cited by 10
Colonic Motor and Sensory Function and Dysfunction
Cook, I. J., Brookes, S. J., & Dinning, P. G. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00098-6 · Cited by 10
Recent Updates on the Treatment of Constipation
Ryu, H. S., & Choi, S. C. (2015) · Intestinal Research · doi:10.5217/ir.2015.13.4.297 · Cited by 11
“In a study of 620 patients with CC, participants receiving 2 or 4 mg of prucalopride for 12 weeks had increased one or more CSBMs per week compared to patients in the control group.(21) In another trial of 713 patients with CC, administration of 2 or 4 mg of prucalopride increased frequency of three or more CSBMs per…”
Result(EFSA), E. F. S. A. (2015) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2015.en-758 · Cited by 9
Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands
Nuijten, M. J. C., Dubois, D. J., Joseph, A., & Annemans, L. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00067 · Cited by 9
“Given its proven effectiveness when laxatives have failed to provide adequate relief (Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009) the cost of prucalopridemay be justified by a favorable incremental cost-effectiveness ratio (ICER).”
BackgroundMethodInfluentialDamodaran, I., Hui, K. O., Nordin, A. S. A., Yee, A. H. A., Gill, J. S., Francis, B., Azhar, F. L., & Sulaiman, A. H. (2020) · Healthcare · doi:10.3390/healthcare8040533 · Cited by 9
New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety
Camilleri, M. (2011) · Canadian Journal of Gastroenterology · doi:10.1155/2011/670484 · Cited by 9
Self-citationYao, J., Yan, X., Chen, L., Li, Y., Zhang, L., Chen, M., & Li, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906403 · Cited by 9
“Severe chronic constipation (SCC) has distinct duration and severity of symptoms over mild and transient types, generally associated with weekly spontaneous bowel movements (SBMs) of <2 times (6).”
BackgroundHuman studies of anorectal sensory function
Knowles, C. H. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1847-5 · Cited by 10
“Such patients are dependent thence on digitally assessing the rectum and aiding evacuation with manual measures or enemas; this deficiency is embodied within the ‘spontaneous complete bowel movement’ outcome measure used in some major pharmacological trials [8].”
Motility Disorders and Hirschsprung Disease
(2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00324-9 · Cited by 10
van Schaick, E., Benninga, M. A., Levine, A., Magnusson, M. O., & Troy, S. M. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.236 · Cited by 9
Pharmacological treatment for antipsychotic-related constipation
Every‐Palmer, S., Newton‐Howes, G., & Clarke, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011128 · Cited by 10
Pharmacologic Treatment of Irritable Bowel Syndrome with Predominant Constipation
Kim, D.-H., Song, H. Y., Nam, K., & the Korean Society of Neurogastroenterology and Motility (2025) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2025.002 · Cited by 9
Lembo, A. J., Simons, M. L., Loesch, J., Hamza, E., Graff, E. L., Quigley, E. M. M., & Rao, S. S. C. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18198 · Cited by 8
“14,15 In another non-drug multicentre, sham-controlled randomized controlled trial (RCT), 16 active acupuncture was shown to be better than sham acupuncture in severe chronic constipation where this was defined as having two or less CSBM/week.”
Pharmacoeconomic study of chronic constipation in a secondary care centre
Walsh, C. H., Murphy, J., & Quigley, E. M. M. (2014) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-014-1204-2 · Cited by 8
Assessment of treatment response in chronic constipation clinical trials
Ervin, C. M., Fehnel, S. E., Carson, R. T., Johnston, J. J., Shiff, S. J., Kurtz, C. B., Mangel, A. W., & Baird, M. J. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s58321 · Cited by 9
Emerging drugs for irritable bowel syndrome
Shekhar, C., & Whorwell, P. J. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903222279 · Cited by 9
“The beneficial effects of prucalopride seen in chronic constipation [47,48,50] and opioid-induced constipation [51] have not been evaluated in IBS but the findings in the above studies suggest these benefits are likely to be applicable to patients with IBS and constipation.”
BackgroundBeckenboden und anale Inkontinenz
Kroesen, A. J. (2013) · Der Chirurg · doi:10.1007/s00104-012-2348-0 · Cited by 8
Liu, B., Wang, Y., Wu, J., Mo, Q., Wang, W., He, L., Yan, S., & Liu, Z. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-260 · Cited by 8
“Severe chronic constipation is defined as two or fewer spontaneous, complete bowel movements (SCBMs) per week, hard stool and a sensation of straining during defecation [4].”
On behalf of the NIHR CapaCiTY working group, Grossi, U., Stevens, N. J., McAlees, E., Lacy‐Colson, J., Brown, S. R., Dixon, A. R., Tanna, G. L. D., Scott, S. M., Norton, C. S., et al. (2018) · Trials · doi:10.1186/s13063-018-2456-3 · Cited by 8
Jandee, S., Wetwittayakhlang, P., & Boonsri, P. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15127 · Cited by 8
Options thérapeutiques médicamenteuses et diététiques actuelles
Ducrotte, P. R. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(09)71527-1 · Cited by 9
Salamone, S., Liu, R., & Staller, K. D. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001772 · Cited by 7
Management of chronic constipation in the elderly
Vasanwala, F. F. (2009) · The Singapore Family Physician · Cited by 7
Zhang, Y., Yin, F., Xu, L., Li, Y.-F., Chen, J., Liu, H., Zheng, Q., & Li, L. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001303 · Cited by 8
Dysmotility of the Small Intestine and Colon
Camilleri, M., & Szarka, L. A. (2008) · Wiley eBooks · doi:10.1002/9781444303254.ch47 · Cited by 9
Self-citationLefebvre, R. A., Ferrero, S., Colen, I. V., Dhaese, I., Camerini, G. B., Fulcheri, E., & Remorgida, V. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01438.x · Cited by 7
Efficacy of Traditional Chinese Medicine in Functional Constipation
Whiting, R. L., & Ford, A. C. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.14 · Cited by 7
“This may explain, in part, their response rate of only 8p, which appears to be somewhat lower than in other placebo-controlled FC trials ((”
Wood, P. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0694-y · Cited by 7
Zhang, J., & Zhang, P.-F. (2024) · Medicine · doi:10.1097/md.0000000000040137 · Cited by 6
“[19,39,40] 4.”
InfluentialEffect of prucalopride on sildenafil‐induced inhibition of esophageal peristalsis in healthy adults
Wong, M., Liu, T., Yi, C., Hung, J., Lei, W., Liang, S., Orr, W. C., & Chen, C. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15305 · Cited by 6
Non-pharmacological strategies to treat irritable bowel syndrome: 2022 update
Bonetto, S., Boano, V., VALENZI, E., Saracco, G. M., & Pellicano, R. (2022) · Minerva Gastroenterology · doi:10.23736/s2724-5985.22.03202-8 · Cited by 7
THE TREATMENT OF CONSTIPATION.
(1911) · The Lancet · doi:10.1016/s0140-6736(01)40439-9 · Cited by 6
Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases
Katzka, D. A., Loftus, E. V., & Camilleri, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.77 · Cited by 6
Self-citationTrastornos funcionales y motores digestivos
Mearin, F., Rey, E., & Balboa, A. (2013) · Gastroenterología y Hepatología · doi:10.1016/s0210-5705(13)70048-7 · Cited by 8
Eguchi, T., Yoshizaki, T., Ikeoka, S., Takagi, M., Fujinami, M., Matsuda, T., Yamaguchi, T., Nonaka, T., Amioka, S., Katayama, N., et al. (2020) · Digestive Diseases · doi:10.1159/000512745 · Cited by 6
Developments and Advances in Gastrointestinal Prokinetic Agents
Dale, J. W., Hollingworth, G. J., & McKenna, J. M. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00018-7 · Cited by 7
A quantitative systems pharmacology model of colonic motility with applications in drug development
Das, R., Wille, L., Zhang, L., Chen, C., Winchester, W. J., Selimkhanov, J., Wykosky, J., Apgar, J. F., Burke, J. M., Rogge, M. C., et al. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09651-6 · Cited by 6
Shah, A., Morrison, M., & Holtmann, G. (2018) · Indian Journal of Gastroenterology · doi:10.1007/s12664-018-0912-3 · Cited by 6
Bajaj, J. S., Brenner, D. M., Cai, Q., Cash, B. D., Crowell, M. D., DiBaise, J. K., Gallegos-Orozco, J. F., Gardner, T. B., Gyawali, C. P., Ha, C. Y., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000709 · Cited by 6
4-Substituted and 1,4-Disubstituted Piperidines
Vardanyan, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805157-3.00005-3 · Cited by 5
Hamatani, T., Noda, N., Takagaki, T., Yodo, Y., Kawai, H., Kakuyama, H., Kaji, Y., & Fujio, Y. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.778 · Cited by 5
Norton, C. S., Bannister, S., Booth, L. R., Brown, S. R., Cross, S., Eldridge, S. M., Emmett, C., Grossi, U., Jordan, M., Lacy‐Colson, J., et al. (2023) · Colorectal Disease · doi:10.1111/codi.16738 · Cited by 5
“Chronic constipation was defined according to pragmatic criteria: broadly those employed for recent pivotal trials of prokinetics [21, 22] and UK guidance [ 23 ].”
MethodFernández, L. M. B., Prizont, R., & Soifer, L. (2013) · PubMed · Cited by 5
Pharmacotherapy in Patients with Chronic Constipation
Kim, S. J., & Park, K. S. (2017) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2017.70.2.64 · Cited by 6
Lembo, A. J., & Ullman, S. P. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00018-4 · Cited by 9
Developing insulin-like peptide 5-based antagonists for the G protein-coupled receptor, RXFP4
Wu, H., Handley, T. N. G., Hoare, B. L., Hartono, H. A., Scott, D. J., Chalmers, D. K., Bathgate, R. A. D., & Hossain, M. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116239 · Cited by 5
Recent Advances in the Management of Difficult Constipation
Lacy, B. E., Levenick, J. M., & Crowell, M. D. (2012) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0269-1 · Cited by 6
Mikami, T., Komada, T., Sugimoto, H., Suzuki, K., Ohmi, T., Kimura, N., Naganeo, R., Nakata, E., Nakatani, K., Toga, T., et al. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.006 · Cited by 5
“In fact, prucalopride, a highly selective 5-HT4 receptor agonist, significantly and consistently improved bowel function, associated symptoms and satisfaction in the patients with severe chronic constipation (Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009).”
BackgroundImpacto del estreñimiento crónico en la calidad de vida: mucho más importante de lo que parece
Mearin, F. (2013) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2012.11.009 · Cited by 5
Current Issues on the Treatment of Chronic Constipation
Hong, K. S., Jung, K. W., Lee, T. H., Lee, B. E., Park, S., Shin, J. E., Kim, S., Park, K. S., & Choi, S. C. (2014) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2014.64.3.148 · Cited by 5
Laine, M., Sirén, J., Koskenpato, J., Punkkinen, J., Rantanen, T. K., Typpö, I., Kokkola, A., & Sallinen, V. J. (2017) · Scandinavian Journal of Surgery · doi:10.1177/1457496917748222 · Cited by 5
The Long and Short of a Constipation-Reducing Medication
Moss, A. J. (2008) · New England Journal of Medicine · doi:10.1056/nejme0802873 · Cited by 5
The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus
De Fano, M., Baluganti, S., Manco, M., Porcellati, F., Fanelli, C. G., & Bassotti, G. (2025) · Nutrients · doi:10.3390/nu17193038 · Cited by 4
Xiong, Z., Yan, S., Liu, S., & Liu, Z. (2025) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2025.04.004 · Cited by 5
Lembo, A. J., Staller, K. D., Boules, M., Feuerstadt, P., Spalding, W. M., Gabriel, A., Youssef, A., Xie, Y., Terreri, B., & Cash, B. D. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241299731 · Cited by 4
Magen-Darm-Mittel und Lebertherapeutika
Mössner, J. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_31 · Cited by 4
Constipación crónica. Conceptos actuales desde la fisiopatología hasta el tratamiento
García‐Zermeño, K. R. (2021) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/zrrj9030 · Cited by 8
“En un análisis de seguimiento de los tres estudios pivote, 86,87,88 en los que se dejó tratamiento continuo (hasta 18 meses) a los pacientes que habían respondido durante doce semanas, se demostró que el 40-50% de los pacientes no tuvieron necesidad de consumir laxantes.”
BackgroundEguchi, T., Inatomi, O., Shintani, S., Momose, K., Sako, T., Takagi, M., Fumihara, D., Inoue, K., Katayama, N., Morisawa, T., et al. (2024) · JGH Open · doi:10.1002/jgh3.70019 · Cited by 4
“21,23 24-29 However, it is unknown whether elobixibat can be used effectively and safely in patients who were refractory to these, single mode of action laxatives.”
Diagnostik und Therapie gastrointestinaler Funktionsstörungen bei Diabetes mellitus
Keller, J. (2013) · Der Diabetologe · doi:10.1007/s11428-013-1066-7 · Cited by 4
Li, Y., LI, L. S., Zhang, X. L., ZHANG, Y., Xu, J., & Zhu, J. (2015) · Physiological Research · doi:10.33549/physiolres.932863 · Cited by 4
Mearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2017) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2017.01.001 · Cited by 6
Hung, J., Yi, C., Liu, T., Lei, W., Wong, M., & Chen, C. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12755 · Cited by 4
“Its efficacy has been demonstrated in the effective management of severe chronic constipation without significant side-effects.(10,11) As prucalopride acts in promoting colon motility, we hypothesized that prucalopride in a single dose of 45 mL NaP could be as efficient as the standard 90 mL NaP in split doses for bow…”
BackgroundObstipation – Pathophysiologie, Diagnostik, Behandlung
Müller-Lissner, S. A. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0670-5209 · Cited by 4
“[17] Camilleri M, Kerstens R, Rykx A et al.”
BackgroundBasnayake, C., Kamm, M. A., Salzberg, M. R., Khera, A. J., Liew, D., Burrell, K., Wilson-O'Brien, A. L., Stanley, A., Talley, N. J., & Thompson, A. J. V. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.105828 · Cited by 4
Bloating and Abdominal Distension: Exploring Hidden Depths and Insights
Pichetshote, N., & Rezaie, A. R. (2020) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-020-00288-w · Cited by 5
Saps, M., Nurko, S., Benninga, M. A., Lorenzo, C. D., Garza, J. M., Thapar, N., Richards, K., Lee, J. J., & Altepeter, T. A. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003191 · Cited by 4
“Recently, trials of prucalopride (6,11) demonstrated that despite a similar effect size in children and adults, the results of pediatric studies were not statistically significant, possibly due to limited sample size.”
ResultWang, W.-M., Wang, X.-L., Liu, Y., Sun, Y.-J., Liu, X., Yan, Y., & Liu, Z.-S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.818258 · Cited by 4
“SBM is defined as a bowel movement that occurred without any medication or intervention to assist within the previous 24 h (33).”
BackgroundDerakhchan, K., Lou, Z., Wang, H., & Baughman, R. (2023) · Drugs in Context · doi:10.7573/dic.2022-6-1 · Cited by 4
Treatment and Management of Gastrointestinal Disorders
Montgomery, G., Patel, A., & Pfeil, S. A. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.010 · Cited by 4
The use of Resolor (prucalopride) for chronic constipation in women
Woodward, S. (2012) · British Journal of Nursing · doi:10.12968/bjon.2012.21.16.982 · Cited by 4
Systematic review of acupuncture for functional constipation
Zhang, W., Sun, J., Pei, L., Wu, X., Lu, C., & Jiao, D. (2014) · Journal of Acupuncture and Tuina Science · doi:10.1007/s11726-014-0756-z · Cited by 4
“Regardless of certain treatment effects, long-term use of the above drugs may cause drug dependence, melanosis coli, and laxative-dependent constipation, etc.([10]) In foreign countries, many constipation patients turn to acupuncture when they don’t respond to Western medications([11]).”
BackgroundDiagnosis and Treatment of Constipation
Jeon, H. H., & Park, H. (2012) · Korean Journal of Medicine · doi:10.3904/kjm.2012.83.5.568 · Cited by 4
“되었으며 가장 흔하게 보고된 부작용은 두통과 복통이었다 [61-63].”
Evidence-based guideline development in paediatric gastroenterology
Tabbers, M. M. (2011) · UvA-DARE (University of Amsterdam) · Cited by 4
Metadata
- Authors
- Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Camilleri, Michael
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-29
- Volume
- 358
- Issue
- 22
- Pages
- 2344-2354
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068454300
- Cited by
- 576
- References
- 36
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 28 · 2020: 28 · 2019: 19 · 2018: 29 · 2017: 33 · 2016: 38 · 2015: 33 · 2014: 46 · 2013: 50 · 2012: 49
- FWCI
- 45.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- prucalopride, serotonin receptor agonists, 5-HT4 receptor agonist, stool frequency, treatment-related adverse events, cardiovascular safety
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Benzofurans, Chronic Disease, Constipation, Defecation, Double-Blind Method, Electrocardiography, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Serotonin Receptor Agonists, Laxatives, Serotonin 5-HT4 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.